IntuitionLabs

INTUITIONLABS / RESEARCH & PRACTICAL GUIDANCE

E2B(R3) ICSRs: A Guide to Pharmacovigilance Reporting

> Build practical AI for pharma and biotech with IntuitionLabs. We help life-science teams turn complex information and workflows into useful software, governed knowledge systems and AI tools.

Published by IntuitionLabs · 2026-01-09 · e2b(r3) · icsr · pharmacovigilance · ich e2b(r3) · electronic reporting · drug safety · hl7 · eudravigilance · data harmonization

Original article: https://intuitionlabs.ai/articles/e2b-r3-icsr-reporting-standard



In this article

1. Executive Summary
2. Introduction and Background
3. E2B(R3) Standard and ICSR Message Structure
4. Overview of E2B(R3)
5. ICSR Data Elements and Code Systems
6. ICSR Operations: Generation, Exchange, and Partners
7. Case Intake and Database Capture
8. Regulatory Exchange Systems
9. Business and Legal Framework
10. Stakeholder Roles and Case Access
11. Data Validation and Quality Control
12. Tracking and Case Coordination Across Partners
13. Case Studies and Evidence
14. Validation and Quality Assurance in Detail
15. Tracking Cases Across the Network
16. Implications, Challenges, and Future Directions
17. Conclusion

[Revised April 28, 2026] Reviewed for currency in April 2026. ISO/ICH E2B(R3) has been the mandatory ICSR submission format in the EU since 30 June 2022. **[Corrected October 2026]** FDA's adverse event system, formerly FAERS and now the FDA Adverse Event Monitoring System (AEMS), has required E2B(R3) for electronic premarketing (IND) ICSRs since 1 April 2026; for postmarketing ICSRs it accepted E2B(R2) through 30 September 2026 and requires E2B(R3) for submissions via ESG NextGen from 1 October 2026 (www.fda.gov). MedDRA references were updated to the current release cycle (version 29.0 in March 2026, 29.1 in September 2026).

Executive Summary

Individual Case Safety Reports (ICSRs) are the backbone of pharmacovigilance – detailed reports of adverse drug reactions involving one patient. Over the past decades, international health authorities and industry stakeholders have harmonized ICSR reporting formats and processes to improve patient safety. The current global standard is the ISO/ICH **E2B(R3)** format, an XML-based model derived from HL7 version 3. E2B(R3) offers a rich, structured framework for exchanging ICSRs among marketing-authorization holders (MAHs), clinical trial sponsors, and regulatory agencies. It replaces earlier formats (such as E2B(R2)) with expanded fields, standardized terminology, and enhanced interoperability (www.clinicalleader.com) (www.pharmexec.com). Robust validation rules, unique identifiers, and audit trails track each safety case as it passes through safety databases, national systems (e.g. EudraVigilance, FAERS), and global repositories (e.g. WHO’s VigiBase).

This report provides an in-depth examination of E2B(R3) and ICSR operations: how case data are structured, exchanged, validated, and tracked across stakeholders. Beginning with background on ICSR reporting and the evolution of E2B standards, we analyze the data model and content of E2B(R3) messages. We review the global reporting ecosystem – the roles of regulatory frameworks (e.g. EU regulations, FDA guidances), safety databases (EudraVigilance, FAERS), and supporting technologies. Key topics include message structure (sections C–H of an E2B(R3) ICSR), controlled vocabularies (MedDRA, WHO Drug Dictionary, ISO IDMP), and new features of R3 (e.g. **null flavors** for missing data, attachments of supplementary documents, and longer narratives) (www.pharmexec.com) (www.pharmexec.com).

The report also covers operational processes: case intake and coding, data entry and quality checks, electronic submissions, and cross-stakeholder data sharing policies. We examine validation and business rules that ensure data consistency (with references to FDA and EMA standards) (www.fda.gov) (www.ema.europa.eu), and mechanisms for case tracking (unique safety report numbers, acknowledgment messages, and regulatory dashboards). Through case examples and aggregated data (e.g. VigiBase usage of E2B format (pmc.ncbi.nlm.nih.gov)), we show how standardized reporting improves signal detection and pharmacovigilance analytics (pmc.ncbi.nlm.nih.gov). Finally, we discuss future directions – from fully digital AE surveillance and AI-assisted processing, to potential expansion of ICSR standards – and conclude with strategic recommendations.

Throughout, all claims and descriptions are supported by authoritative sources, including regulatory guidances, scientific literature, and industry analyses (www.fda.gov) (www.ema.europa.eu). This comprehensive guide aims to equip pharmacovigilance professionals, informatics specialists, and regulators with a detailed understanding of E2B(R3) ICSR operations and the state of global safety case reporting.

Introduction and Background

Pharmacovigilance is the science of detecting, assessing, understanding, and preventing adverse effects or other drug-related problems. A cornerstone of pharmacovigilance is the **Individual Case Safety Report (ICSR)** – a detailed record of an adverse drug reaction in a single patient, typically reported by a healthcare professional or consumer. Historically, ICSRs were captured on paper forms (e.g. CIOMS forms) and exchanged manually between companies and regulators, a process prone to delays and inconsistencies.

Recognizing the need for harmonization, the International Council for Harmonisation (ICH) issued the original E2B guideline (Step 4 in 1996) to define an electronic standard for ICSR exchange. Over time, the E2B specification evolved: Revision 2 (R2) expanded early electronic data interchange in the 2000s; the current standard, **E2B(R3)**, was finalized in 2013 (www.ema.europa.eu) (www.fda.gov). E2B(R3) is codified as *ISO 27953-2:2011 (E2B(Ich) Implemented)*, and it leverages HL7 version 3 messaging and ISO Identification of Medicinal Products (IDMP) pillars to enable rich, globally consistent ICSR data (www.pharmexec.com) (www.ema.europa.eu). Notably, E2B(R3) is built on the HL7 Reference Information Model (RIM), providing an object-oriented structure for adverse event data (docs.oracle.com) (docs.oracle.com).

In parallel, regulatory frameworks mandated electronic reporting. For example, the European Union's pharmacovigilance legislation requires MAHs to submit ICSRs to the EMA's EudraVigilance system in E2B(R3) format, using standardized ISO terminology (including EDQM dose form/route) (www.ema.europa.eu)

(www.ema.europa.eu). As of 30 June 2022, it became **mandatory** in the EU to use ISO/ICH E2B(R3) for all ICSRs, replacing the older format (www.ema.europa.eu) (www.ema.europa.eu). Other regions are in transition: the U.S. FDA has issued guidance and tools for sponsors to submit both clinical trial and post-marketing ICSRs in E2B(R3), with compliance expected in the near future (www.fda.gov) (www.fda.gov). Similarly, Japan's PMDA and Canada's Health Products Regulators have been moving toward E2B(R3) harmonization (often by adopting ICH guidelines or ISO standards). Meanwhile, the World Health Organization's global database, VigiBase, receives ICSRs (often forwarded by member countries) in electronic formats that largely digitize or align with E2B(R3) content.

By formalizing case contents into discrete data elements and codes, the E2B(R3) standard enables automated processing, validation, and analysis.This structure enhances data quality and interoperability: " [a]dherence to the E2B standard allows worldwide exchange of information quickly and accommodates direct database-to-database data transmission" (www.clinicalleader.com). Indeed, a 2025 study of VigiBase found that roughly **80% of reports in its full dataset** were in E2B format (pmc.ncbi.nlm.nih.gov), reflecting broad international uptake of the standard. As one industry expert notes, the main benefit of E2B(R3) over its predecessors is "capturing of detailed data" and "standardization of data" knowledgeably shared with all stakeholders (www.pharmexec.com).

This report proceeds to unpack the E2B(R3) model and its practical implementation. We first detail the **data structure** of an E2B(R3) ICSR (Section 3) – the segments, fields, and code systems used. Next, we examine the **case lifecycle and exchange processes** across stakeholders (Section 4), including how ICSRs flow from reporters through corporate systems to regulators. Section 5 covers **data validation and quality controls**, such as schema checks and business rules required by agencies. Section 6 discusses **tracking and management** of case data throughout the network of partners. Case studies and statistical evidence (Section 7) illustrate real-world impacts. Finally, we consider forward-looking developments (Section 8) and conclude with implications for safety monitoring. Throughout, citations to regulatory documents, peer-reviewed studies, and guidelines substantiate our discussion (www.fda.gov) (docs.oracle.com).

E2B(R3) Standard and ICSR Message Structure

Overview of E2B(R3)

The ICH E2B(R3) guideline defines the **data elements and message specifications** for electronic ICSRs (www.fda.gov) (www.ema.europa.eu). It is a consensus document; in effect, a "common envelope" and dictionary for safety data transmission across regions (www.fda.gov) (www.pharmexec.com). Technically, E2B(R3) uses HL7's V3 messaging. Each ICSR is encoded in an XML message consistent with the ISO 27953 ICSR schema (an ISO standard derived from ICH E2B) (www.fda.gov) (www.ema.europa.eu). The message is composed of multiple parts: a **batch wrapper** (if sending multiple reports), then a **message wrapper** with sender/receiver information, and finally the **CaseSafetyReport** content itself which holds patient event data.

Within the CaseSafetyReport, information is organized into defined sections and elements. (For brevity, section labels are summarized; details follow.) The Argus Safety documentation, for instance, maps E2B(R3) sections as follows:

- **Section C (Administrative data):** C.1 *Identification of the Case Safety Report* (report ID, creation date, case type, version), C.2 *Primary Sources* (reporter type, qualifications, address), C.3 *Sender* (MAH or EV registration IDs), C.4 *Literature References*, C.5 *Study Identification* (for clinical trial reports) (docs.oracle.com).
- **Section D (Patient):** patient characteristics (age, sex, weight, country, outcome of event) (docs.oracle.com).
- **Section E (Events/Reactions):** one or more adverse reactions or relevant medical events (coded using MedDRA, with seriousness and outcome) (docs.oracle.com).
- **Section F (Tests/Procedures):** any clinical or laboratory test results pertinent to the adverse event (e.g. vital signs, lab values).
- **Section G (Drugs):** drug information for *suspect*, *concomitant*, or *interacting* drugs (name, identifier, dose, route, indication, therapy dates) (docs.oracle.com).
- **Section H (Narrative):** an unstructured textual case narrative and supplementary attachments (e.g. lab reports, autopsy pdfs) (www.pharmexec.com).

This rich structure is far more detailed than the old E2B(R2) schema (which had simpler sections A through E). Notably, E2B(R3) moved certain data elements from “case” to “event” level, expanded lists of codes, and allows new fields such as literature references and expanded study/trial identifiers (www.pharmexec.com). The **Table 1** below highlights key differences between R2 and R3 **ICSR formats**.

Feature	E2B(R2)	E2B(R3)
Underlying Standard	Older ICH E2B specification (pre-ISO)	HL7 v3 / ISO 27953 (ICH E2B(R3) standard) (www.ema.europa.eu) (www.fda.gov)
Message Sections	Segments A–E (Case ID, patient, event, etc.)	C.1–C.5 (administrative), D (patient), E (event), F (tests), G (drugs), H (narrative) (docs.oracle.com) (docs.oracle.com)
Creation Date/Version	Used *SafetyReportVersionNumber*	Uses *DateOfCreation* timestamp (CCYYMMDDhhmmss+/-ZZzz) (www.pharmexec.com)
Drug/Exposure Fields	No explicit “not administered” code	Adds code “Drug Not Administered” for certain trial and med-error cases (www.pharmexec.com)
Narrative Length	Up to 20,000 characters	Extended to 100,000 characters (www.pharmexec.com)
Attachments	Not supported	Supports embedded files (pdf, jpg, etc.) as attachments (www.pharmexec.com)
Null Flavors (Missing Data)	Not used	Introduces “nullFlavor” attributes to indicate why data is missing (e.g. “unk” for unknown) (www.pharmexec.com)
Terminology Standards	MedDRA, WHO DD (versioned per region)	MedDRA, WHO DD, and ISO IDMP codes (EDQM, SNOMED, etc.) for products and terms (www.pharmexec.com) (www.ema.europa.eu)

Feature	E2B(R2)	E2B(R3)
Global Harmonization	Partially region-specific implementations	ICH consensus plus region-specific guides (e.g. EU ICSR Implementation Guide) (www.pharmexec.com)
Backward Compatibility Tools	–	Backward/Forward Compatibility (BFC) mapping and transformation tools provided (www.fda.gov)

Table 1: Comparison of key features in ICSR E2B(R2) vs E2B(R3) formats. *ICSR sections* updated per HL7 design, with E2B(R3) enabling greater data richness (e.g. attachments) and standardized terminology. Sources: ICH/ISO specifications and EMA/FDA guidance (www.fda.gov) (www.pharmexec.com).

ICSR Data Elements and Code Systems

E2B(R3) defines a vast set of data elements (on the order of thousands of fields, many optional) organized by concept and section in the message. Some highlights:

- **Case Identification (Section C.1):** Each report includes a unique report identifier assigned by the sender, plus dates (creation, primary receipt) and report type (e.g. spontaneous, literature). For example, the “Date of Creation” is recorded as a full timestamp (replacing the old version-number scheme) (www.pharmexec.com). Region-specific packet (batch/document) IDs are also included at the wrapper level.
- **Primary Source (C.2) & Sender (C.3):** The person or system reporting the case is coded (e.g. healthcare professional, patient, literature) with qualification and country. The **Organization** that submits the report (e.g. MAH name and safety unit) is specified using identifiers from data sources like ISO 27269 (ICH OID). Agreements between partners (such as joint controllers) are documented per GDPR norms.
- **Literature & Studies (C.4–C.5):** If the ADE was found in a journal or safety bulletin, a literature citation can be linked. Similarly, clinical trial ICSRs carry StudyID, Sponsor, subject number, if applicable. (Regulations require SUSARs in trials to be reported via E2B to regulators and sponsors.)
- **Patient (Section D):** Demographics (age, gender, weight, country) and relevant medical history are coded. Patient outcomes (recovered, fatal, etc.) and any risk factors (e.g. pregnancy) are captured. Fields follow HL7 data types, and age can be given with precision (years, months, days).
- **Reaction/Event (Section E):** Each reported adverse event or outcome is coded using MedDRA terminology (e.g. “Anaphylactic shock”, “Liver injury”). For each event, fields include start and end dates, seriousness criteria (death, hospitalization, congenital anomaly, etc.), and outcome (resolved, not resolved). The ICH guide notes that some data elements moved from the case level to the event level (for example, seriousness is per event) (www.pharmexec.com).
- **Drugs (Section G):** Drug administration details are structured. *Suspect drugs* are listed with name (coded using the WHODrug global dictionary or national codes), dose form, route, dosage, and therapy dates. Concomitant medications and vaccines can also be listed. Notably, ISO IDMP standards align

with E2B(R3) for product identification, promoting consistent coding of active substances and formulations (www.pharmexec.com). The addition of EDQM vocabulary (ISO 11239) covers dosage forms and routes (www.ema.europa.eu), as mandated in EU law.

- **Tests and Procedures (Section F):** Relevant former lab results (e.g. blood chemistries, imaging) may be included. Each result is coded by test name and value. This structured capture aids in automated signal algorithms.
- **Narrative and Attachments (Section H):** A free-text narrative describes the case in detail. In E2B(R3), this field length was quintupled (from 20,000 to 100,000 characters) to allow fuller descriptions (www.pharmexec.com). Crucially, R3 permits embedding attachments (scanned reports, ECG charts) as binary objects in the XML message (www.pharmexec.com). The guideline limits attachments to "documents that add value" (e.g. lab reports, autopsy results). This was a major enhancement over R2, enabling richer case information to travel unchanged.

The following table summarizes the **main sections and examples of contents** in an E2B(R3) ICSR:

Section	Contents / Examples
C.1 Identification	Unique report ID, case version/timestamp, report type, submission date
C.2 Primary Source	Reporter role (e.g. physician, consumer, literature), qualifications, contact info
C.3 Sender	Reporting organization (MAH) identifier and contact; country of sender
C.4 Literature	References to publications or abstracts related to the case
C.5 Study ID	Clinical trial identifier, site, subject code (for trial reports)
D Patient	Age, gender, weight, country; patient outcome (recovered, fatal, unknown)
E Reaction(s)	MedDRA-coded adverse events, seriousness (criteria), dates, outcome of each event
F Tests/Procedures	Coded lab tests and values (e.g. ALT=250 U/L), relevant procedures or findings
G Drugs	For each suspect/interacting medicine: drug code (WHO-DD), batch number, dose, route, indication; also concomitants
H Narrative/Attachments	Free-text case summary; embedded documents (PDF/jpg lab reports, images) (www.pharmexec.com)

Table 2: ICSR (E2B(R3)) data sections and example contents. Sections C1–C5 cover administrative/sender information; D–G cover patient-event data; H is narrative/attachments. *Sources:* ICH E2B(R3) Implementation Guide and vendor documentation (docs.oracle.com) (docs.oracle.com).

Controlled Terminologies

To ensure consistency and facilitate analysis, ICSRs use standard code sets and dictionaries. Among these are **MedDRA** (for adverse event terms), **WHODrug** or national drug codes (for medicinal products), and **MedDRA query (SMQ)** grouping for complex queries. The E2B(R3) specification fixes controlled fields to specific value sets (e.g. gender, seriousness criteria). For dosage forms and routes, the EU requires EDQM via

ISO 11239 (www.ema.europa.eu). For product identification, the ISO IDMP standards govern assigning unique IDs to substances (ISO 11238), products (11239), packaging (11240), and dosages (11242), which will eventually feed into E2B messages. (In practice, many companies map to IDMP identifiers to populate E2B optional fields such as “IngredientAdministrationSite”).

The ICH E2B(R3) Implementation Guide itself provides full data dictionaries and XML schemas. It also comes with an **Appendix for Backward/Forward Compatibility (BFC)** (www.fda.gov), which defines how to convert between R2 and R3 messages. This is important because during transition periods, stakeholders often needed to interoperate across formats. EMA even provided toolkits to convert R2 messages to R3 (and vice versa) to ease system upgrades (www.pharmexec.com).

ICSR Operations: Generation, Exchange, and Partners

Case Intake and Database Capture

At the corporate level, PV staff retire paper forms and enter case details into a safety database (such as Oracle Argus, ARISg, Veeva Vault Safety, or similar). The **minimum elements** for any electronic ICSR are: one identifiable patient, one identifiable reporter, at least one adverse event, and at least one suspect drug (docs.oracle.com). Companies follow medical review workflows to finalize case data: confirming seriousness, coding reaction terms (MedDRA) and drugs (WHO-DD), adding narratives, and verifying completeness.

Once internally verified, a case is *locked* for regulatory submission. The safety database then **generates an E2B(R3) XML package** for each target region. Many PV systems allow configuration of output profiles (e.g. selecting R2 or R3 format as needed). During generation, each case becomes one or more E2B transmissions: for example, one case might be transmitted separately to the EMA, FDA, and WHO UMC, depending on where market authorizations exist or where the patient resides.

The exchange of these ICSRs is typically **fully automated** via electronic gateways and often uses secure web services or file transfer protocols. For instance, companies upload ICSRs through the **EudraVigilance Gateway** for EU reports, and via FDA’s electronic submission portal or API for the United States (www.fda.gov). These systems apply additional technical controls (X.509 certificates, HTTPS/TLS) to protect patient data. The E2B(R3) architecture supports acknowledgments: on successful receipt, a regulatory system can send an ACK (HL7-based) back to the sender, sometimes with a new **safety report ID** assigned by the agency. This creates an audit trail and avoids data loss.

Notably, expedited ICSRs from **clinical trials** (typically *SUSARs*) follow the same E2B(R3) structure but include the study sponsor and site details. Regulations (e.g. the EU Clinical Trials Regulation and FDA’s IND safety reporting rules) require expedited reporting of qualifying safety information, such as suspected unexpected serious adverse reactions, within defined timelines; the reportable categories and routes differ by jurisdiction. The study identification section (C.5) of the ICSR includes protocol and site codes, and companies often set up **reconciliation processes** to ensure trial EDC (electronic data capture) systems and safety

databases are synchronized (www.clinicalleader.com). ThoughtSphere and others have highlighted the need for automated “safety case reconciliation” between EDC and PV databases, so that every electronically captured Serious Adverse Event is reliably transmitted to regulators (www.clinicalleader.com).

Regulatory Exchange Systems

Different regions have their own primary systems that collect and analyze ICSRs:

- **EudraVigilance (EMA, EU):** The central database for the European Economic Area. Post-2017 upgrade, it requires ISO/ICH E2B(R3) format and EDQM coding (www.ema.europa.eu) (www.ema.europa.eu). MAHs and national authorities submit ICSRs to EudraVigilance (post-authorisation serious cases from inside and outside the EEA and non-serious cases from within the EEA, plus SUSARs from clinical trials). The system makes reports available to the relevant member states, and EMA provides WHO’s Uppsala Monitoring Centre (UMC) with a defined set of data elements for ICSRs originating within the EEA, for global signal detection (www.ema.europa.eu). EMA provides a **Data Analysis System (EVDAS)** portal, where MAHs and regulators can query and download relevant cases for their products (www.ema.europa.eu).
- **AEMS, formerly FAERS (FDA, US):** FDA's adverse event database, now named the FDA Adverse Event Monitoring System (AEMS). E2B(R3) has been required for electronic premarketing (IND) ICSRs since 1 April 2026; for postmarketing ICSRs, FDA accepted E2B(R2) through 30 September 2026 and requires E2B(R3) for submissions via ESG NextGen from 1 October 2026 (www.fda.gov). FDA has published **Technical Specifications** and **Validator tools** to help sponsors prepare R3 submissions (www.fda.gov) (www.fda.gov). Companies without E2B gateway capability may instead enter ICSRs manually through FDA's Safety Reporting Portal web form (www.fda.gov).
- **VigiBase (WHO-UMC, global):** The WHO’s global ICSR repository, collecting individual reports from over 170 member countries. Each national program submits ICSRs periodically (often using WHO’s VigiFlow tool or manual uploads). VigiBase does not require strict E2B(R3) format – in fact, historically submissions varied – but efforts align its database fields with the ICH core data elements. WHO UMC’s **pregnancy algorithm study** (see Section 7) relied on ICSRs in “the International Council on Harmonisation (ICH) E2B transmission format” to leverage structured fields (pmc.ncbi.nlm.nih.gov). Today, as regional regulators standardize on R3, most global reports are likely E2B-compliant: ~80% of VigiBase reports were in E2B format even before 2025 (pmc.ncbi.nlm.nih.gov).
- **Other national systems:** Many countries rely on large MHRA (Yellow Card, UK), TGA (Australia), PMDA (Japan), Health Canada, etc., with varying integration into E2B. Some still accept E2B(R2) or local custom formats, but most are planning migration to E2B(R3) or harmonizing with WHO’s standards. For example, EMA reflected that “ [e]xchange of ICSRs between EMA, NCAs, MAHs and trial sponsors” is fully electronic in EV (www.ema.europa.eu).

In practice, meeting the obligations means each ICSR might be sent to multiple agencies. For instance, a serious case in a U.S. patient involving a product authorised in both the U.S. and the EU may need to be reported to FDA and, as a serious non-EEA case, to EudraVigilance, depending on each jurisdiction's reporting rules. Coordinated partners (e.g. multinational companies, co-marketed products) often share ICSR

responsibility, requiring case-reconciliation across corporate safety databases. Newer tools enable “direct DB-to-DB” exchanges so that data entered once can populate all reports needed (www.clinicalleader.com). Nevertheless, MAHs typically maintain internal tracking (via unique case IDs) to correlate submissions to different systems.

Business and Legal Framework

E2B(R3) reporting is enforced by law. In the EU, Regulation (EU) No 1235/2010 and implementing rules (e.g. Reg. 520/2012) explicitly mandate the use of the ISO ICSR standard and terminologies (www.ema.europa.eu) (www.ema.europa.eu). As of mid-2022, submission of side-effects must follow those ISO/ICH requirements (www.ema.europa.eu). The FDA and many other regulators similarly expect compliance with ICH guidelines in their territories. Guidance documents clarify region-specific **business rules** (cut-off dates, exempt ICD-10 coding, etc.), with EMA providing updated rules spreadsheets and reference instances (www.ema.europa.eu) (www.ema.europa.eu). Failure to meet format and timeline requirements can lead to regulatory enforcement.

From a privacy standpoint, E2B messages must protect patient privacy. Personal identifiers are strongly discouraged; any Protected Health Information (PHI) beyond age and gender must be minimal or pseudonymized in ICSRs. The EU access policy explicitly mentions GDPR considerations when disclosing ICSR data (www.ema.europa.eu) (www.ema.europa.eu). For example, MAHs accessing EudraVigilance narratives must sign confidentiality undertakings (www.ema.europa.eu).

Stakeholder Roles and Case Access

Different “partners” in the PV network have varied roles and data needs. EMA’s EudraVigilance policy illustrates this:

- **Marketing Authorization Holders (MAHs)** can access via EVDAS the ICSR data *for their own products* – a defined set of ICSR data elements for medicines for which they hold an EEA marketing authorisation, with access to all data elements only for the cases they submitted themselves (www.ema.europa.eu) (www.ema.europa.eu). This helps them validate signals and fulfill periodic report obligations. MAHs must also record in their safety database when they view or act on ICSR data retrieved from EV (www.ema.europa.eu).
- **National Competent Authorities (NCAs)** in the EEA can access all data elements of all ICSRs submitted to EudraVigilance, not just those they submitted. They have full data access (subject to local rules) via the same EVDAS tools (www.ema.europa.eu). Similarly, under a data transfer arrangement, EMA provides VigiBase with a defined set of data for ICSRs originating in the EEA, enhancing global surveillance (www.ema.europa.eu).
- **Public/Academia:** The EU also made aggregated or de-identified ICSR data available for research (e.g. in SPOR datasets or through restricted web portals). Consumer reporters (patients) can submit ICSRs via national reporting portals, but once in corporate/regulatory hands, the flow is primarily one-way (outward).

Each stakeholder relies on the standardized structure to interpret and act on cases. For example, regulators routinely query EV to detect safety signals or review narrative summaries, taking advantage of the coded data. The proactive “open data” stance in recent years has led to publication of ICSR counts and trends (Annual Reports) (www.tepsivo.com).

Data Validation and Quality Control

Ensuring the integrity of case data is critical. Both **schema validation** and **business-rule validation** occur at multiple points:

- **Schema (Technical) Validation:** The E2B(R3) XML is checked against the ISO/I2B(R3) XSD schemas before submission. Modern PV systems include built-in XML validators, and agencies provide tools. For example, FDA offers an online *E2B(R3) Validator* where submitters can test their XML files for correctness (www.fda.gov). Similarly, the EU’s EV technical suite automatically rejects messages with malformed structure or invalid codes. These checks enforce compliance with data types, required fields, controlled vocabularies, and file encoding (e.g. UTF-8).
- **Business Rule Validation:** Beyond format, agencies impose content rules. The EMA issued a detailed *Business Rules* spreadsheet (rev. Aug 2024) that enumerates conditional requirements: e.g. if “seriousness=death”, then an outcome date must be present; or if a suspect drug has a start date, an end date should have a non-negative interval. EV will flag errors such as a missing patient identifier (at least one of several identifying elements is required, not necessarily sex or age) or invalid age formats where a permitted nullFlavor is not used correctly (www.pharmexec.com). FDA’s *Regional Implementation Guide* similarly lists allowed values (e.g. event seriousness codes) and local data elements for US-specific fields. (www.fda.gov)
- **Code List/Terminology Checks:** Consistency in terminology is enforced. MedDRA versioning is crucial; typically, regulators specify the coding version to use (MedDRA is released twice a year, in March and September; version 29.0 was released in March 2026 and 29.1 in September 2026 (alt.meddra.org), and regulators such as EMA define when senders must move to a new version) and will reject or request updates if an obsolete term is used. Drug coding is likewise checked against WHO-DD. In the EU, using EDQM terms for dosage form/route is mandatory from 2022 (www.ema.europa.eu). Any new code set releases (SNOMED transitions, IDMP MPID lists) require synchronization, and many agencies update their training on new term sets.
- **Duplicate Detection:** A subtle but important aspect of quality is deduplication. Both EV and FAERS employ algorithms to detect duplicate reports (multiple submitted copies of the same case). This often relies on matching key fields (patient age, event date, drug, reporter) and cross-checking global IDs. Companies also try to avoid duplicates by internal checks (if the same case is reported by two friends of the patient, etc.). Since R3 allows full inclusion of foreign regulatory identifiers, it should in principle help match duplicates by standard IDs – though in practice legacy problems remain.

- **Forward/Backward Compatibility (BFC):** During transition, an ICSR might need to be converted between versions. The FDA published *BFC Mapping style sheets* to transform R2<->R3 (www.fda.gov). These systematically map fields (for example, transforming R2's "legacyCaseID" into R3's sender case IDs). Companies must be aware of these differences when interfacing with partners still on older formats.
- **Regulatory Reporting Timeliness:** Besides structural validation, agencies enforce time-based rules. For example, serious unexpected ADRs must be reported within specified days of awareness. Systems often generate **expedited report forms** from the same ICSRs data, but the R3 XML itself may be held for batch submission. Regulatory submission compliance is tracked by date stamps in the ICSR messages and by logs in the safety database. Audit trails in corporate PV systems must capture every change, approval, and transmission.

All these checks ensure that when the case data arrives at a partner's system, it is largely complete and standardized. However, real-world experience shows issues can slip through. EMA and industry surveys have noted common validation failures: missing mandatory fields, misaligned patient age/sex combos, or incompatible file encodings. Therefore, extensive testing is routine – sponsors test their E2B(R3) output in **organization-specific test environments** (e.g. EMA's XCOMP environment (www.ema.europa.eu), FDA's staging) using synthetic case data. This helps catch schema and business rule violations before the final submission.

Tracking and Case Coordination Across Partners

Once an ICSR is in the electronic relay, its journey must be tracked carefully. Key methods include:

- **Safety Report Identifiers:** Every ICSR has one or more unique IDs. The MAH assigns an internal "Case ID" when filing initially. On submission to a regulator, the receiving system may attach its own "Safety Report Number". For example, EudraVigilance issues an EV *Case ID*; FAERS creates an AERS ID. When cases are forwarded between systems (e.g. EV→WHO), those identifiers may shift. Tracking across partners thus relies on mapping these IDs. ICH E2B(R3) carries the sender's safety report unique identifier (C.1.1), a worldwide unique case identification number (C.1.8.1) that stays the same on follow-up transmissions, and identifiers from previous transmissions (C.1.9.1). This helps each party reconcile follow-ups: a subsequent E2B message keeps the worldwide unique case number of the initial ICSR (docs.oracle.com).
- **Message Identifiers and Acknowledgments:** Each E2B transmission has a message ID (in the wrapper). Regulators typically generate an HL7 ACK message referencing that ID to acknowledge receipt or report failures. Companies log these ACKs (often emails or portal receipts) and match them to cases. Loss of an ACK prompts re-transmission.

- **System Logs and Audit Trails:** Within corporate PV databases, workflows assign statuses to each case: e.g. “Entered”, “Completed”, “Submitted to EMA”, “Submitted to FDA”. These statuses, along with timestamps and user IDs, provide traceability. In large organizations, dedicated safety case managers often coordinate multi-region reporting, ensuring all required markets have received the ICSR.
- **Regulatory Dashboards:** E2B(R3) has enabled regulators to build sophisticated tracking tools. In EudraVigilance, for instance, MAHs can log in to see the status of their reports – whether accepted, accepted with errors, or rejected. They can download XML receipts that detail any validation warnings. EMA’s EV Access Policy also mandates that regulators record any actions taken on cases (requests for follow-up, signals raised). API endpoints (as in the EV Access Policy) allow automated reconciliation of MAH databases with regulator records.
- **Cross-Agency Collaboration:** When adverse events involve multiple countries, harmonized reporting prevents gaps. For example, EU regulations no longer require MAHs to send ICSRs to each individual NCA if already submitted to EV (www.ema.europa.eu); EV distributes the reports internally and assigns a unique “EV case number”. Similarly, under a data transfer arrangement, EMA provides WHO-UMC with a defined set of data for ICSRs originating in the EEA. The worldwide unique case identification number (C.1.8.1) in E2B(R3) serves as a common reference for a case. Ultimately, the goal is that any stakeholder – MAH, regulator, or WHO – can reference the same case unambiguously.

Through these mechanisms, a safety case can be **tracked across partners**. Internally, large companies often build “notification engines” that alert affiliates when a case is transmitted abroad, and integrate global case history.

Case Studies and Evidence

To illustrate these concepts, consider some data and examples from recent literature:

- **E2B(R3) Uptake and Impact:** A 2018 *Pharmaceutical Executive* article by Prashant Dhanavade (Sciformix) examined the EV transition to R3. It found that R3 significantly expanded the data captured (more fields, attachments, null flavors), which “helps improve quality and completeness of ICSR data” (www.pharmexec.com). The author noted that despite a costly upgrade for MAHs, the *value* lies in interoperable data: “more data can be passed to regulatory authorities or MAHs, making the information much more valuable…leading to better patient outcomes” (www.pharmexec.com). They provided a table of EV changes (Table 1) that matches our Table 1 features above (www.pharmexec.com) (www.pharmexec.com).
- **Validation Benefits:** A 2025 Drug Saf article assessed an algorithm to extract pregnancy cases from VigiBase. Interestingly, it found the algorithm recalled far more cases when limited to ICSRs that “adhere to the ICH E2B format” (91% recall) versus the general database (75%) (pmc.ncbi.nlm.nih.gov). In other words, structured, standardized data (E2B-compliant) substantially improved case-finding. This highlights that high-quality, harmonized case data can enhance pharmacovigilance analytics. Moreover,

the study reported that **80%** of VigiBase case reports were submitted in E2B format (pmc.ncbi.nlm.nih.gov), demonstrating widespread adoption; indeed, we see that proportion persisting even in tailored datasets (79–81% in subsamples).

- **Stakeholder Experience:** The EMA has provided feedback on E2B(R3) readiness: users in 2021–2022 underwent training courses on EudraVigilance and E2B from EMA experts. EMA reported that after go-live, MAHs no longer need to report to NCAs separately (a significant efficiency gain) (www.ema.europa.eu). We also note from EMA's communications that EV now directly feeds WHO, relieving member states of "forwarding cases" duties (www.ema.europa.eu).
- **Technical Implementation:** Preparing for FDA's R3 requirements has meant testing with FDA's validation resources and revising internal tools, because R3 features such as null flavors and attachments require updates to e-submission mappings. (FDA has published technical specifications and a transition schedule for these requirements (www.fda.gov).)

While some of the cited evidence is from guidance rather than study (given the nature of the topic), it consistently underscores that E2B(R3) is becoming the de facto standard. The data above – 80% E2B usage globally (pmc.ncbi.nlm.nih.gov), mandated EU conversion (www.ema.europa.eu), and positive signal detection effects (pmc.ncbi.nlm.nih.gov) – provide quantitative backing. Case documentation (e.g. EMAs ICSR IG and Business Rules (www.ema.europa.eu) (www.ema.europa.eu)) also constitute a body of "best practice" evidence for how data should be structured and exchanged.

Validation and Quality Assurance in Detail

Regulatory agencies have imposed stringent controls on data quality. The EMA's **Business Rules** example: if a submitted ICSR lacks a required element (e.g. patient outcome when "death" is ticked), EV will return an *error list* to the sender. EMA updated its guidance to clarify that Section C (administration) must align with R3 provisions – for instance, sender and case identifiers (C.1.1, C.1.8.1) must follow the R3 rules. Mandatory and conditionally mandatory fields are enumerated in the business rules (for example, at least one patient identifier must be provided). Faulty cases can be nullified or corrected through follow-up submissions that keep the original worldwide case number.

The FDA's **Validator tool** allows companies to upload their E2B(R3) XML in a sandbox mode. It performs XML schema checks and known business rule checks (FDA's regional data element rules) and provides instantaneous pass/fail results (www.fda.gov). Such tools are commonly used as a pre-submission check.

Even with strict checks, imperfections remain. Industry surveys (e.g. by DIA or PV congresses) report common pitfalls: incorrect "sender OIDs" due to certificate updates, outdated MedDRA versions, or misuse of country codes. Moreover, the freedom to use null flavors in R3 can lead to data gaps if overused. Therefore, companies often maintain supplementary quality teams that audit samples of ICSRs for content accuracy.

In terms of **internal quality metrics**, companies track ICSR completeness and on-time submission rates. Analytics dashboards may monitor: *what percentage of ICSRs pass all schema checks on first attempt*, *average time from case receipt to submission*, and *discrepancies found on regulator feedback forms*.

Continuous improvement cycles refine database forms (e.g. adding field validations) and training programs, driven by the goal of minimizing rejection.

Tracking Cases Across the Network

A central question is how a single safety case is *coordinated* among all stakeholders. The typical case workflow runs from report intake to transmission to multiple agencies, with feedback loops and global aggregation. Key points:

- **Acknowledgments and Versioning:** When a regulator receives an ICSR, it returns an acknowledgment (ACK) message stating whether the report was accepted or rejected; the acknowledgment may include a receiver-assigned local report number (ACK.B.r.2). These are important to retain. In E2B(R3), follow-up reports keep the same worldwide unique case identification number (C.1.8.1), identifiers from previous transmissions are carried in C.1.9.1, and C.1.10.r links separate but related reports. Thus, case tracking relies on incrusting multiple IDs: the sponsor's own Case ID, the initial report's global ID, and any regulatory IDs attached along the path.
- **Shared Views:** Some systems offer shared visibility. In the EU, if a safety event affects multiple MAHs (e.g. co-marketed product), an affiliate can log into EudraVigilance to view the case. This ensures each partner knows the case status (e.g. if a SPC update or RMP was submitted). CMOs or CROs managing multiple product portfolios similarly value dashboards that reconcile their internal case list with what regulators have received.
- **Case Consolidation:** In practice, duplicate cases (same patient reported by doctor and hospital, for instance) are consolidated after regulatory receipt. For example, if FAERS receives two reports believed to be the same event, it may label one as duplicate and close it. MAHs also engage in safety triage: ICSR reporting guidelines (e.g. ICH E2D) require them to "link" follow-ups to initial reports and to close cases when possible. The sophistication of E2B(R3) supports this through linking fields, but ultimate case management still requires human review for merging duplicates or closing resolved cases.
- **Audit Trails:** Every exchange leaves a record. Companies usually log the Time Stamp, Recipient, and File Name/ID for each outbound message. Regulators similarly timestamp receivals and any data corrections. This audit trail is crucial for inspections: regulators can trace back which data was submitted on what date. In fact, many agencies keep a copy of the XML on file; MAHs are often asked during inspections to show correspondence with authorities (for example, showing that a certain ADR was alerted to FDA on a given date).

In summary, a typical ICSR data workflow runs as follows: safety cases originate from reports, are processed in corporate systems, then are submitted via E2B(R3) to regulators; agencies may exchange reports internally and with WHO; and feedback includes acknowledgments and data extracts (e.g. EVDAS case lists).

Overall, "tracking across partners" has improved markedly under E2B(R3). By having common data fields and identifiers, stakeholders can coordinate case follow-ups more transparently. For example, a follow-up transmission keeps the case's worldwide unique case identification number (C.1.8.1), making it visible to all

parties that this is a **follow-up**. These linkages ensure the case narrative and outcome updates propagate to all repositories without losing context.

Implications, Challenges, and Future Directions

The transition to E2B(R3) has broad implications for pharmacovigilance:

- **Improved Data Mining:** With standardized fields, signal detection algorithms can operate more effectively. The pregnancy exposure study (pmc.ncbi.nlm.nih.gov) is one example: structured data (pregnancy codes, obstetric histories) inside E2B(R3) messages allowed automated case-finding with high accuracy. In general, richer data enable powerful analytics (e.g. data mining, machine learning) that can flag safety signals earlier.
- **Regulatory Collaboration:** The move to R3 in major jurisdictions (the EU since 2022, FDA in 2026) fosters harmonization, although R3 is not yet a universal mandate and some regulators still accept E2B(R2). Over time, agencies may converge on a unified international safety database. The closer alignment of FDA and EMA on R3 reduces duplication – in future, one could imagine a single global report engine, or at least easier mutual recognition of submissions.
- **Operational Efficiency:** Companies report initial ("going live") pains but long-term gains. Instead of compiling multiple paper or E2B(R2) packets by country, they now can generate one canonical R3 set and "slice" it for different destinations. Workflows are streamlined: e.g., a follow-up entered in an American database can be included in the same global case thread. MAHs no longer send duplicate data to each EU NCA separately – EV handles redistribution internally (www.ema.europa.eu), cutting administrative work.

However, challenges remain:

- **Technical Complexity:** Implementing R3 is non-trivial. Safety systems had to be upgraded (new XML generators, vocabularies, OID repositories) and staff retrained. SMEs who juggle multiple reporting standards face a heavier technical burden. Tools like the FDA validator and EMA test environments mitigate some risk, but small companies may struggle.
- **Data Volume:** More fields mean more data to collect. For example, capturing pregnancy exposure now involves multiple fields (conception date, trimester, outcomes); companies must adjust case intake forms accordingly. This can lengthen case entry time. The grim reality during COVID-19 was an explosion of ICSRs, straining both data entry teams and EV/FAERS capacity.
- **Regulatory Variation:** While ICH provides the core, each region still has nuances (e.g. FDA may have unique fields for U.S. biostudies (www.fda.gov), EU requires EDQM terms (www.ema.europa.eu), etc.). Companies must maintain logic to handle these divergences. There is risk that misinterpretation of a business rule (e.g. local value sets) could sabotage a submission.

Future Directions: The pharmacovigilance community is already looking beyond E2B(R3):

- **FHIR and Real-Time Reporting:** The HL7 FHIR standard (targeted at healthcare interoperability) has draft profiles for adverse event reporting (e.g. ICSR bundles). Some stakeholders explore FHIR-based ICSR transmission, which could integrate more directly with EHRs and hospital systems. However, broad adoption may be years away, and until then E2B(R3) remains the legal standard.
- **Artificial Intelligence:** AI tools for case intake (e.g. auto-coding from narratives) and signal detection are advancing. These tools rely on high-quality structured data, reinforcing the value of E2B(R3). Regulators are also exploring AI for paperwork (e.g. FDA's use of natural language processing on narratives), which again benefits from standardized input.
- **Continuous Improvement:** ICH may in future publish a further revision (R4) to address any gaps; for example, better capturing patient-reported outcomes or integrating genomic information. Meanwhile, programs like the ISO SPOR (Substance/Product Outcome Reference Metadata) may feed into ICSRs via common identifiers.

Conclusion

E2B(R3) represents a mature, feature-rich standard for ICSR exchange and has become the linchpin of modern pharmacovigilance reporting. Its adoption has required significant effort from regulators and industry, but the benefits are clear: more complete case data, seamless sharing across borders, and better tools for safety monitoring (www.pharmexec.com) (pmc.ncbi.nlm.nih.gov).

Key components of an effective E2B(R3) workflow include: robust PV database processes to populate data fields accurately; rigorous validation against schemas and business rules; and careful coordination of case identifiers and submission timelines. The standardized sections (C–H) ensure that everyone speaks the "same language" when referring to case details (docs.oracle.com) (docs.oracle.com). As one expert summary states: "Without harmonization, the existence of multiple submission formats [would] be a barrier to efficient exchange" – E2B(R3) solves this by providing a **common envelope** (www.yumpu.com).

In practice, companies that have mastered E2B(R3) reporting find that it streamlines compliance (no more transcriptions between formats) and enables data-driven safety science. The next frontier will be leveraging these harmonized data at scale – cross-case analytics, AI triage, and integration with real-world evidence sources. Regulated stakeholders should therefore continue to invest in technical readiness (e.g. evolving their E2B mappings and testing) and in processes for case reconciliation, to fully realize the promise of digital safety case reporting.

Sources: Regulatory guidances (EMA, FDA, ICH), industry analyses, and peer-reviewed pharmacovigilance research provide evidence and specifics used throughout this report (www.fda.gov) (www.ema.europa.eu) (pmc.ncbi.nlm.nih.gov). Additional data (e.g. ICSRs volumes, case examples) are drawn from published reports.

Source links

Links cited in this article, in order of first appearance. Full addresses are provided for readers using extracted text.

1. https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/fda-adverse-event-monitoring-system-aems-electronic-submissions
2. https://intuitionlabs.ai/articles/analytical-method-validation-ich-q2
3. https://intuitionlabs.ai/articles/case-report-form-library
4. https://www.clinicalleader.com/doc/safety-case-transmission-reconciliation-0001
5. https://www.pharmexec.com/view/ich-e2b-r3-eudravigilance
6. https://intuitionlabs.ai/articles/gamp-5-ai-ml-validation-gxp
7. https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-electronic-submissions-e2br3-standards
8. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/pharmacovigilance-research-development/eudravigilance/change-management-eudravigilance-system
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC12423168/
10. https://intuitionlabs.ai/articles/ai-ind-cta-drafting-pharma
11. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2br3-electronic-transmission-individual-case-safety-reports-implementation-guide-data-elements-and
12. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/pharmacovigilance-research-development/eudravigilance/access-eudravigilance-data
13. https://www.ema.europa.eu/en/ich-e2b-r3-electronic-transmission-individual-case-safety-reports-icsrs-data-elements-message-specification-implementation-guide-scientific-guideline
14. https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance
15. https://docs.oracle.com/en/industries/health-sciences/argus-interchange/8.2.2/aeoba/minimum-requirement-electronic-report-generation.html
16. https://www.tepsivo.com/blog/eudravigilance-2020-annual-report-key-figures/
17. https://alt.meddra.org/files_acrobat/whatsnew_29_1_English.pdf
18. https://www.yumpu.com/en/document/view/24438626/implementation-guide-for-electronic-transmission-of-individual-case-

THE PUBLISHER

About IntuitionLabs

IntuitionLabs is an AI consulting, custom software development and data engineering firm serving pharmaceutical, biotechnology, medical-device and other life-science organizations. We work with clinical, regulatory, medical-affairs, commercial, quality and IT teams to connect technology decisions with the work people need to accomplish.

AI consulting and adoption

Our AI enablement services cover readiness assessments, use-case selection, governance and policies, team workshops, adoption measurement and ongoing advisory support. We help organizations structure the information layer behind AI: source material, context, permissions and maintained knowledge that make generated answers useful and reviewable. Private LLM inference and hosted AI options support teams evaluating how to operate AI with appropriate control over their data and infrastructure.

Software, data and life-science workflows

IntuitionLabs develops custom software for pharma and biotech, integrates enterprise systems, and builds data engineering and business intelligence solutions. Areas of focus include AI agents, regulatory research, medical writing, medical affairs, CMC information, competitive intelligence and clinical-document workflows. Our eTMF intelligence work includes cross-system reconciliation and inspection-readiness support.

Enterprise platforms and regulated delivery

We provide Veeva services, application support, managed services, integrations and custom applications, alongside enterprise content work involving platforms such as Egnyte. For regulated workflows, our services include GxP enablement, computer-system validation and software development addressing 21 CFR Part 11 requirements. The applicable controls, validation responsibilities and acceptance criteria are defined for each engagement.

Work with IntuitionLabs

Explore AI enablement, pharma and biotech software development, data engineering and BI, and Veeva services. Contact IntuitionLabs to discuss your workflow, information sources and implementation needs.

IntuitionLabs publishes educational research to help life-science teams make informed technology decisions. Coverage of a product or organization does not imply a client relationship, endorsement or partnership.

Website: https://intuitionlabs.ai

This article is educational. Verify consequential medical, legal, financial, regulatory and technical decisions with appropriate professionals and the cited primary sources. Company services are described separately from the article's research findings.